Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

We are pleased to announce that Maiwald Intellectual Property will participate as a Platinum Partner at the upcoming Life Sciences Strategy Summit on IP & Exclusivity, taking place in the Infinity Hotel & Conference Resort Munich from 13–15 October 2025.

Dr. Eva Ehlich, Partner at Maiwald, will serve as Event Co-Chair and Panel Chair.
She will lead a key session on Antibody Exclusivity Challenges Considering the Post-G2/21 and Amgen vs Sanofi Landscape

The session will address:

• The role of “surprising technical effect” in antibody patents
• Impact of G2/21 on inventive step analysis
• Legal implications of the Amgen vs Sanofi decision
• IP and ownership challenges in antibody-drug conjugates (ADCs)
• New approaches to defining the objective technical problem in antibody cases

Dr. Ehlich will be joined by senior legal and scientific representatives from Novartis, Amgen, and Sterne, Kessler, Goldstein & Fox.

In addition, Dr. Anja Fux will chair a session on EPO Board of Appeal Cases and the Effect Upon the Life Sciences Sector (Cases: G1/24, G2/21, T 1977/22, G1/23)

Discussion points include:

• The implications of G1/24 and G1/23 for the scope and enforceability of life sciences patents
• The evolving plausibility standard following G2/21
• T 1977/22 and its relevance to open-range sufficiency

With over 400 participants expected, including in-house counsel and legal experts from originator, generic, and biotech companies, the summit provides a key platform for discussion and strategic exchange at the interface of law, science, and innovation.

More information and the full agenda are available here.